Showing 15 posts of 89 posts found.


NICE rejects CAR-T therapy Kymriah for DLBCL in adults

September 19, 2018
Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia

The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …


FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)

September 17, 2018
Sales and Marketing AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases

AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who …


Jazz Pharma’s acute myeloid leukaemia drug scores EU approval

August 29, 2018
Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma

Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …


NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

NICE recommends Pfizer’s Besponsa in rare leukaemia following review

August 9, 2018
Sales and Marketing NICE, Pfizer, leukaemia, pharma

Pfizer has revealed that NICE has finally decided to recommend its CD22-targeting monoclonal antibody Besponsa (inotuzumab ozogamicin) in the treatment …


The cause of the most common form of childhood cancer found

May 22, 2018
Manufacturing and Production, Research and Development biotech, drugs, leukaemia, pharma, pharmaceutical

Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise …


Porton Biopharma opens new leukaemia drug production facility

May 1, 2018
Manufacturing and Production Porton Biopharma, leukaemia, pharma

Porton Biopharma Limited (PBL) has officially opened the doors of its new fermentation facility. John Glen, MP for Salisbury and …


FDA expands indication of Teva’s Trisenox for acute promyelocytic leukaemia

January 16, 2018
Manufacturing and Production, Sales and Marketing FDA, Teva, acute promyelocytic leukaemia, leukaemia, pharma

Teva has announced that its Trisenox (arsenic trioxide) injection has been awarded US approval from the FDA in combination with …

Pfizer’s Bosulif scores US green light in leukaemia sub-type

December 21, 2017
Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma

Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …


Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds

December 13, 2017
Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma

The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …


Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no

December 6, 2017
Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma

Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …


Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint

September 19, 2017
Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical

Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …


Spotting Leukaemia

September 7, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, leukaemia, pharma, pharmaceutical

Leukaemia is a household name, but how much do we really understand about it? Not enough, says Bethany Torr, Campaigns …

FDA halts trial after first CAR T-associated patient death

September 6, 2017
Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical

French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …

Pfizer’s leukaemia drug gets opposing regulatory decisions on either side of the Atlantic

August 18, 2017
Medical Communications, Sales and Marketing Besponsa, Cancer, FDA, NICE, Pfizer, leukaemia, pharma, pharmaceutical

Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …

Latest content